leiomyosarcoma research uk

Together, we will find a cure.

We support research and education to enable better treatment and outcomes for Leiomyosarcoma cancer patients.

---------------------------------

MEET THE TRUSTEES

COLIN GRANDISON

TREASURER

Colin retired in 2019 having spent 44 years in Banking the last 10 years of which were as an Auditor for Citibank in Canary Wharf. Diagnosed with LMS in upper right arm in February 2022 which was excised in May same year. Currently under a regime of regular CT scans at Royal Marsden, London.

MAISIE ENGLAND

CHAIR OF TRUSTEES

Maisie is experienced in connecting researchers together on large international research programs.

She was diagnosed with LMS in her bowel in 2023 and found the limited treatment and surveillance options disappointing. This has given Maisie the drive to find more solutions to cure LMS; she believes that research is the key to this success.

JULIA CASIMO

SECRETARY

Julia is an experienced chartered accountant, director and trustee. In her previous career she ran a successful accountancy firm in Liverpool. She was diagnosed with uLMS in 2016, retiring shortly after her diagnosis, and continues to undergo treatment. As well as acting as a Trustee of LMS Research UK she is Trustee/Treasurer of several other charities. She is also a member of the Sarcoma UK grant committee.

LEO CASIMO

ASSOCIATE TRUSTEE

Leo has extensive experience in the charity sector, including senior leadership roles focused on operations, strategic growth and project delivery. His mother's diagnosis with LMS in 2016 fuels his commitment to his role as Trustee at Leiomyosarcoma Research UK. He brings expertise in income generation and operational management at a medical charity.

MICHAEL PENDRY

ASSOCIATE TRUSTEE

Michaels wife Kelly was diagnosed with Uterine Leiomyosarcoma and was given just 3 months to live but bravely fought for a further 2 years. Raising two children Michael is passionate about keeping Kellys legacy of doing everything possible to find a cure and making sure LMS is at the forefront of any conversation regarding rare cancers.